Gerresheimer (ETR:GXI) Shares Down 0.5% - Here's Why

Key Points

• Shares fell 0.5% to €21.22 on Tuesday with an intraday low of €20.48, and trading volume rose about 63% above average (≈229,938 shares traded).
• The stock shows cheap valuation metrics (market cap $726.5M, P/E 6.36, PEG 0.82) but high leverage and tight liquidity (debt-to-equity 164.82, quick ratio 0.40, current ratio 0.98).
• Gerresheimer manufactures medicine packaging and drug-delivery devices (prefillable syringes, vials, inhalers, autoinjectors) and operates three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies.

Gerresheimer AG (ETR:GXI - ) shares were down 0.5% on Tuesday . The company traded as low as €20.48 and last traded at €21.22. Approximately 229,938 shares traded hands during mid-day trading, an increase of 63% from the average daily volume of 140,925 shares. The stock had previously closed at €21.32.

Gerresheimer Price Performance

The company has a debt-to-equity ratio of 164.82, a quick ratio of 0.40 and a current ratio of 0.98. The firm has a market cap of $726.51 million, a price-to-earnings ratio of 6.36, a price-to-earnings-growth ratio of 0.82 and a beta of 0.57. The company's fifty day moving average is €19.04 and its two-hundred day moving average is €24.16.

About Gerresheimer

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.